SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community actively discusses bullish technical indicators, including potential "golden cross" formations and chart breakouts. Many investors view LTC as undervalued "digital silver" poised for a significant move, with conversations highlighting its anticipation to break free from current channels and generate strong upward momentum.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is highly active following its recent FDA approval of YARTEMLEA, a first-in-class therapy for a critical transplant complication, which the community views as a game-changing milestone. Discussions are vibrant around the delayed conference call, which many believe signals further positive developments or even potential acquisition interest, reinforcing a strong bullish sentiment and expectations for substantial future value after significant de-risking.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

Alpha Capital Acquisition Co is experiencing massive trading volume and price surges, primarily driven by intense community speculation around a potential merger announcement. Its low float and high short interest are igniting strong discussions about a possible short squeeze, with many comparing its extreme volatility and frequent halts to past SPAC phenomena. Traders are actively debating its upward trajectory amidst caution about typical pump-and-dump dynamics for such volatile plays.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF ($MAGS) is a focal point of market conversation, driven by its leadership in the current technology rally and significant movements within its constituent stocks, such as Elon Musk's recent share purchases in Tesla. Investors are actively discussing its resilience and potential for new highs following a rebound from tariff-related concerns, despite ongoing debates about market concentration. The community remains engaged with MAGS as a core vehicle for exposure to the leading technology innovators, evidenced by frequent options trading and technical analysis.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending due to recent advancements like its quantum-safe state proofs and a partnership with Noah HQ for regulated payment integration, alongside a surge in developer activity. While these developments bolster its long-term outlook for real-world assets and institutional adoption, community sentiment remains highly polarized, with strong opinions on its price trajectory.

SPDR Series Trust - State Street SPDR S&P Regional Banking ETF

SPDR S&P Regional Banking ETF

The SPDR S&P Regional Banking ETF (KRE) is trending amidst strong expectations for Fed rate cuts and ongoing sector consolidation, including significant M&A activity. Community discussion is sharply divided; bulls anticipate further upside from favorable economic conditions and potential deregulation, while bears remain cautious, citing persistent concerns over commercial real estate exposure and rising loan delinquencies. KRE's performance is closely watched as a key indicator for small-cap equities and the broader health of regional economies.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is surging amid escalating market excitement driven by reports of China's upcoming silver export restrictions and robust industrial demand for AI and green technologies. The community is fiercely divided, with many celebrating monumental gains and predicting significantly higher prices due to perceived physical scarcity and dollar debasement, while others warn of a speculative bubble poised for a sharp correction reminiscent of past surges.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics (AQST) is heavily trending as its PDUFA date for Anaphylm, an innovative sublingual epinephrine film, approaches, fueling strong community debate on its market disruption potential. Bulls are highly confident in approval, citing robust clinical data and the absence of an FDA Advisory Committee, while skeptics point to increased short interest and past regulatory hurdles as potential headwinds. The conversation centers on Anaphylm's needle-free convenience challenging traditional auto-injectors and potential competitor products.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is experiencing a surge in trading activity, fueled by broader AI sector momentum and heightened interest in its Gemini-II APU. The community is actively discussing the chip's potential for power-efficient edge AI, especially for defense and drone applications, citing recent government contracts and anticipated multi-modal Large Language Model benchmarks. This positions GSI as a potential disruptor in the expanding market for specialized AI inference hardware.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to excitement over its expanding anticoagulant pipeline, including recent acquisitions and progress for its lead candidate tecarfarin, which has FDA Fast Track and Orphan Drug designations. Community sentiment is sharply divided; while many anticipate significant upside from these developments and its low float, others express strong concerns about ongoing share dilution and the company's persistent need for capital to fund clinical trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Monday...

Oncobiologics (NASDAQ:OTLK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oncobiologics from a "strong sell" rating to a "hold" rating in a research note on Saturday...

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of +4.35% and -101.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Oncobiologics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Oncobiologics (NASDAQ:OTLK - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of...

Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK) will be releasing its Q4 2025 earnings before the market opens on Friday, December 26. (View Earnings Report at...

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Analysts

Shares of Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. One...

Oncobiologics (NASDAQ:OTLK) Stock Price Up 4.6% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Shares Up 4.6% - Time to Buy...

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Should You Buy...

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Equity

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc